QBX258
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $37,123 | 1 | 0 |
| 2017 | $39,900 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $77,023 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND MULTIPLE DOSE PLACEBO CONTROLLED TRIAL TO ESTABLISH THE EFFICACY OF QBX258 COMBINATION OF VAK694 AND QAX576 IN ASTHMA THAT IS INADEQUATELY CONTROLLED WITH INHALED CORTICOSTEROIDS AND LONG ACTING BETA AGONISTS | Novartis Pharmaceuticals Corporation | $77,023 | 0 |
Top Doctors Receiving Payments for QBX258
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Riverside, CA | $77,023 | 2 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $77,023
- Total Doctors 0
- Transactions 2
About QBX258
QBX258 is a drug associated with $77,023 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $37,123 was paid across 1 transactions to 0 doctors.
The most common payment nature for QBX258 is "Unspecified" ($77,023, 100.0% of total).
QBX258 is associated with 1 research study, including "A RANDOMIZED DOUBLE BLIND MULTIPLE DOSE PLACEBO CONTROLLED TRIAL TO ESTABLISH THE EFFICACY OF QBX258 COMBINATION OF VAK694 AND QAX576 IN ASTHMA THAT IS INADEQUATELY CONTROLLED WITH INHALED CORTICOSTEROIDS AND LONG ACTING BETA AGONISTS" ($77,023).